skip to Main Content

Preventative Peptide Vaccine Protocols (PPVP), commonly called preventative cancer vaccines, are designed to help prevent cancer in individuals who have a high risk of developing the disease. Preventative solutions have always taken a back seat to the much larger effort of developing therapeutic treatments for the millions of patients currently living with cancer. The time has come to get in front of this important issue as a way to eliminate cancer in the population altogether.

We understand that cancer is a result of either a genetic disease or a result of a failure of immunosurveillance. PPVPs are a way to prime and reeducate the immune system to target cancer antigens that result from mutations.

Unlike our therapeutic vaccinations, PPVP offers a way for patients to avoid a cancer diagnosis altogether. Similarly to all of our innovative treatment options, PPVP is an experimental approach to cancer prevention. We base all of our treatments on well-tested and well-tolerated therapeutic strategies to give our patients their best fighting chance against cancer.

PPVPs work by targeting the common immunogenic antigens present on most solid tumor types. They are expected to yield an immune response against at least 70% of its targeted antigens. The vaccine would be administered before any cancer diagnosis to boost immunosurveillance and eliminate pre-malignant cells and/or lesions. A PPVP consists of 6 vaccine injections spread 1 month apart, followed by 1 maintenance injection every 6 months.

PPVPs are recommended for the following individuals:

  • People with a family history of breast, ovarian, or prostate cancer
  • People with the BRCA gene mutation
  • Heavy smokers
  • People with significant exposure to the sun or with a history of blistering sunburns

Some individuals are more prone to developing cancer than others due to certain risk factors. These people should also consider a PPVP:

  • Carriers of lynch syndrome
  • People with pre-malignant lesions
  • People who have had precancerous colorectal polyps
  • People with celiac disease
  • Individuals with irritable bowel syndrome
  • Patients who have been diagnosed with HPV
  • Patients living with hepatitis B or C
  • HIV positive and AIDS patients
Back To Top